Skip to main content

Table 3 Circulating polymer concentrations of the different AATD genotypes

From: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease

AATD genotype

AAT polymers (µg/mL)

AAT polymers (%)

AAT (mg/dL)

Patients (n = 70)

 Pi*ZZ treated (n = 11)

42.9 (16)

9.2 (9.6)

73.5 (46.9)

 Pi*FZ (n = 1)

42.1 (–)

6.2 (–)

67.7 (–)

 Pi*ZZ untreated (n = 21)

34.5 (16.2)

14.7 (4.8)

23.1 (5.9)

 Pi*MmaltonZ (n = 1)

22.8 (–)

10.2 (–)

22.2 (–)

 Pi*PlowellZ (n = 1)

15.8 (–)

4.5 (–)

35.3 (–)

 Pi*SZ (n = 13)

14.2 (4.2)

2.39 (0.6)

58.8 (8.3)

 Pi*MZ (n = 13)

9.78 (6.3)

0.98 (0.5)

97 (16.5)

 Pi*SMmalton (n = 1)

6.9 (–)

1.45 (–)

47.9 (–)

 Pi*MMmattawa (n = 1)

5.5 (–)

0.8 (–)

66.9 (–)

 Pi*MMvall d’hebron (n = 1)

4.1 (–)

0.3 (–)

126 (–)

 Pi*MMmalton (n = 2)

2.3 (3.2)

0.2 (0.3)

80.7 (18.5)

 Pi*SS (n = 3)

0

0

84.1 (10.5)

 Pi*SI (n = 1)

0

0

85.0 (–)

Controls (n = 47)

 Pi*MM (n = 35)

1.04 (1.73)

0.06 (0.1)

172.7 (34.3)

 Pi*MS (n = 12)

0.9 (1.7)

0.06 (0.1)

142.7 (20.1)

  1. Values are mean (standard deviation)
  2. AATD alpha-1 antitrypsin deficiency, AAT alpha-1 antitrypsin